[go: up one dir, main page]

WO2012030308A2 - Formulation comprising cellobiose - Google Patents

Formulation comprising cellobiose Download PDF

Info

Publication number
WO2012030308A2
WO2012030308A2 PCT/TR2011/000198 TR2011000198W WO2012030308A2 WO 2012030308 A2 WO2012030308 A2 WO 2012030308A2 TR 2011000198 W TR2011000198 W TR 2011000198W WO 2012030308 A2 WO2012030308 A2 WO 2012030308A2
Authority
WO
WIPO (PCT)
Prior art keywords
cellobiose
pharmaceutical composition
composition according
average particle
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2011/000198
Other languages
French (fr)
Other versions
WO2012030308A3 (en
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP11776267.4A priority Critical patent/EP2611431A2/en
Publication of WO2012030308A2 publication Critical patent/WO2012030308A2/en
Publication of WO2012030308A3 publication Critical patent/WO2012030308A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Definitions

  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a carrier and one or more than one active agents developed in order to be used in the treatment of respiratory tract diseases such as asthma and COPD.
  • the patent numbered EP0464171 disclosed that the particle size of the carrier comprised in the dry powder formulation could be in the range of 5 to 1000 ⁇ . While it is possible to adjust the particle size of the carrier so as to ensure a more effective inhalation, one can also add another excipient along with the carrier.
  • the patent numbered WO8705213 relates to a dry powder formulation comprising a lubricant in addition to the carrier. Both of these patents in the prior art particularly emphasize lactose.
  • lactose is used in the products on the market such as FORADIL® and ASTMEROL®.
  • lactose is a good carrier, it leads to many problems due to its hygroscopic nature.
  • the dry powder formulation may be agglomerated and adhere to the surfaces. Since this adhesion also comprises the active agents, amount of the active agent in the formulation that reaches the patient's mouth decreases, therefore the quality of the treatment.
  • novel formulations that would be developed in order to improve the quality of the treatment and minimize the specified problems.
  • the inventor has surprisingly found that therapeutic effect is increased when long-acting ⁇ 2 - agonist and/or pharmaceutically acceptable derivatives thereof are carried with cellobiose.
  • cellobiose is used as carrier in the dry powder formulations of the present invention, it has been seen that the rate of agglomeration of the formulation and adhesion to the device surfaces is decreased. By this means, the amount of active agent reaching the mouth therefore the lungs of the patient increases. Thus, it provides a more effective treatment with reduced dose frequency.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising long-acting Pa- agonist and/or pharmaceutically acceptable derivatives thereof as active agent and cellobiose as carrier developed in order to be used in the treatment of respiratory diseases such as asthma and COPD.
  • the present invention provides a dry powder formulation comprising long- acting p -agonist and/or pharmaceutically acceptable derivatives thereof and cellobiose.
  • the amount of cellobiose in the dry powder formulation comprising long-acting p 2 -agonist and/or pharmaceutically acceptable derivatives thereof is in the range of 0-50 mg and preferably in the range of 3-20 mg.
  • the present invention provides a medicament in which the average particle size of cellobiose that the pharmaceutical composition comprises is in the range of 0,01 to 1000 ⁇ , preferably in the range of 5 to 500 ⁇ .
  • amount of active agent reaching the mouth and lungs of the patient is increased by adjusting the particle size of the carrier.
  • the present invention provides a pharmaceutical composition comprising cellobiose which has two different particle sizes.
  • the dry powder formulation of the present invention can comprise cellobiose which has two different particle sizes as coarse and fine in addition to the active agent.
  • the active agent can reach the lungs more easily during inhalation.
  • Fine particles adsorb onto the active areas on the coarse particles that the formulation comprises. Fine particles also have active areas. Thus, the number of active areas required for the active agent to adsorb and be carried is increased.
  • coarse particles may get caught in the upper respiratory tract. In this case, the fine particles on the active areas of the coarse particles are released with the active agents and effectively transmitted to the lungs.
  • a formulation lacks fine particles, when the coarse particles get caught in the upper respiratory tract, active agent is released there and cannot reach the lungs.
  • fine particles can fly without coarse particles and remain in the patient's mouth. Consequently, it provides advantages in the treatment that cellobiose comprised in the dry powder formulation of the present invention has two different particle sizes.
  • Average particle size of cellobiose particles comprised in the pharmaceutical composition of the present invention is smaller than 10 ⁇ , preferably smaller than 5 ⁇ and more preferably smaller than 3 ⁇ .
  • Average particle size of the coarse cellobiose particles is in the range of 10 to 1000 ⁇ , preferably in the range of 100 to 600 ⁇ and more preferably in the range of 150 to 300 ⁇ .
  • long-acting p 2 -agonist and/or pharmaceutically acceptable derivatives thereof in the medicament formulation comprises pharmaceutically acceptable solvates, hydrates, enantiomers or diastereomers, racemates, free base, organic salts, inorganic salts, esters, polymorphs, crystalline forms and amorphous forms of long-acting p 2 -agonist or a combination thereof.
  • long-acting 2 -agonist and/or pharmaceutically acceptable derivatives thereof comprised in the dry powder formulation can be selected from a group comprising salmeterol, bambuterol, clenbuterol, formoterol, arformoterol, carmoterol, indacaterol, milveterol, olodaterol or a combination thereof, though it is probably formoterol, arformoterol and carmoterol.
  • amount of the active agent in the dry powder formulation comprising long-acting p 2 -agonist and/or pharmaceutically acceptable derivatives thereof is in the range of 0,01 to 25 ⁇ , preferably in the range of 0,1 to 20 ⁇ and more preferably 0,5 to 15 ⁇ .
  • the present invention provides a medicament comprising long- acting 2 -agonist and/or pharmaceutically acceptable derivatives thereof in micronized sizes.
  • Average particle size of long-acting 2 -agonist and/or pharmaceutically acceptable derivatives thereof comprised in the formulation of the present invention is in the range of 0,01 to 30 ⁇ , preferably in the range of 0,05 to 10 ⁇ and more preferably in the range of 1 to 5 ⁇ . Adjustment of particle sizes is very important for medicaments administered by the inhalation route. Coarse particles can be caught in the upper respiratory tract after inhaled and this makes it harder for the particles to reach the lungs.
  • the present invention provides inhalation of the medicament comprising long-acting ⁇ 2 - agonist and/or pharmaceutically acceptable derivatives thereof as active agent and cellobiose as carrier via dry powder inhalers.
  • the present invention provides inhalation of the dry powder formulation comprising long-acting p 2 -agonist and/or pharmaceutically acceptable derivatives thereof and cellobiose from a capsule or blister.
  • the present invention provides administration of the dry powder formulation comprising long-acting 2 -agonist and/or pharmaceutically acceptable derivatives thereof and cellobiose in aerosol form.
  • aerosol refers to dispersion or suspension of a liquid, solution or solid particles in air or gas.
  • the dry powder formulation can be administered in aerosol form which is characterized by containing propellant gas or not.
  • the dry powder formulation comprising cellobiose can additionally comprise other excipients.
  • excipients can be selected from a group comprising monosaccharides (glucose, etc.), disaccharides (lactose, cellobiose, saccharose, maltose, etc.), oligosaccharides and polysaccharides (dextran, etc.), polyalcohols (sorbitol, mannitol, xyolitol, etc.), salts (sodium chloride, calcium carbonate, etc.), inositol and/or isomers (myoinositol, etc.) or a combination thereof.
  • the pharmaceutical composition comprising long-acting ⁇ 2 - agonist and/or pharmaceutically acceptable derivatives thereof can additionally comprise one or more active agents and/or pharmaceutically acceptable derivatives thereof selected from a group comprising anticholinergic, adrenergic agonist, glucocorticosteroid, xanthine, anti leukotriene, PDEIV inhibitor, EGFR inhibitor, anti-allergic, anti-inflammatory, antihistaminic and antimuscarinic substances.
  • the pharmaceutical composition comprising long-acting ⁇ 2 - agonist and/or pharmaceutically acceptable derivatives thereof can additionally comprise one or more substances and/or pharmaceutically acceptable derivatives thereof selected from a group comprising anticholinergics such as tiotropium, ipratropium, glycopyrronium and oxytropium; p 2 -agonists such as salbutamol, fenoterol, terbutaline, carbuterol and pirbuterol; corticosteroids such as beclomethasone, budesonide, ciclesonide, fluticasone and mometasone; xanthines such as doxyphyllin, theobromine, theophylline and aminophylline; antileukotrienes such as montelukast, pranlucast, zafirlukast, ritolukast, sulukast, tomelukast, verlukast, iralukas
  • the pharmaceutical composition comprising long-acting p 2 -agonist and/or pharmaceutically acceptable derivatives thereof according to the present invention can be used in the treatment of many respiratory diseases, particularly in asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • these respiratory diseases can be, but not limited to, asthma at any stage, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), exacerbation of airway hyperactivity, bronchiectasis, chronic obstructive pulmonary including emphysema and chronic bronchitis, respiratory diseases or lung diseases (COPD, COAD or COLD), pneumoconiosis, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis, byssinosis.
  • This treatment can be prophylactic or symptomatic.
  • the composition of the present invention is especially used for symptomatic treatment of asthma and COPD.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising a carrier and one or more than one active agents developed in order to be used in the treatment of respiratory tract diseases such as asthma and COPD.

Description

FORMULATION COMPRISING CELLOBIOSE
Purpose of the Invention:
The present invention relates to a pharmaceutical composition comprising a carrier and one or more than one active agents developed in order to be used in the treatment of respiratory tract diseases such as asthma and COPD.
Background of the Invention:
Administration of the drugs by the inhalation route has an important place in the treatment of respiratory tract diseases such as asthma and COPD since the drugs given by the inhalation route directly reach the lungs and start their activity there. Active agents are used in pretty little amounts as they directly reach the target area. To this respect, both for production of the formulation and its administration in effective doses, one or more excipients are required in addition to the active agent. Formulation is diluted and carried with the excipients. According to this, formulations comprise excipients more than active agents.
To enable effective inhalation of dry powder formulations, there have been many studies conducted in the prior art in order to select the excipient and adjust the features of the excipient selected such as particle size, percentage by weight. The patent numbered EP0464171 disclosed that the particle size of the carrier comprised in the dry powder formulation could be in the range of 5 to 1000 μιη. While it is possible to adjust the particle size of the carrier so as to ensure a more effective inhalation, one can also add another excipient along with the carrier. The patent numbered WO8705213 relates to a dry powder formulation comprising a lubricant in addition to the carrier. Both of these patents in the prior art particularly emphasize lactose. Furthermore, it is also seen that lactose is used in the products on the market such as FORADIL® and ASTMEROL®. However, although lactose is a good carrier, it leads to many problems due to its hygroscopic nature. With hygroscopic lactose, the dry powder formulation may be agglomerated and adhere to the surfaces. Since this adhesion also comprises the active agents, amount of the active agent in the formulation that reaches the patient's mouth decreases, therefore the quality of the treatment. Today, there is still need for novel formulations that would be developed in order to improve the quality of the treatment and minimize the specified problems. Moreover, there is still need for a simple, more effective treatment with reduced dose frequency. Detailed Explanation of the Invention:
The inventor has surprisingly found that therapeutic effect is increased when long-acting β2- agonist and/or pharmaceutically acceptable derivatives thereof are carried with cellobiose. In the case that cellobiose is used as carrier in the dry powder formulations of the present invention, it has been seen that the rate of agglomeration of the formulation and adhesion to the device surfaces is decreased. By this means, the amount of active agent reaching the mouth therefore the lungs of the patient increases. Thus, it provides a more effective treatment with reduced dose frequency.
The present invention provides a pharmaceutical composition comprising long-acting Pa- agonist and/or pharmaceutically acceptable derivatives thereof as active agent and cellobiose as carrier developed in order to be used in the treatment of respiratory diseases such as asthma and COPD.
In another aspect, the present invention provides a dry powder formulation comprising long- acting p -agonist and/or pharmaceutically acceptable derivatives thereof and cellobiose.
According to the present invention, the amount of cellobiose in the dry powder formulation comprising long-acting p2-agonist and/or pharmaceutically acceptable derivatives thereof is in the range of 0-50 mg and preferably in the range of 3-20 mg.
In another aspect, the present invention provides a medicament in which the average particle size of cellobiose that the pharmaceutical composition comprises is in the range of 0,01 to 1000 μπι, preferably in the range of 5 to 500 μηι. In the present invention, amount of active agent reaching the mouth and lungs of the patient is increased by adjusting the particle size of the carrier.
In another aspect, the present invention provides a pharmaceutical composition comprising cellobiose which has two different particle sizes. The dry powder formulation of the present invention can comprise cellobiose which has two different particle sizes as coarse and fine in addition to the active agent. Thus, the active agent can reach the lungs more easily during inhalation. Fine particles adsorb onto the active areas on the coarse particles that the formulation comprises. Fine particles also have active areas. Thus, the number of active areas required for the active agent to adsorb and be carried is increased. In another aspect, coarse particles may get caught in the upper respiratory tract. In this case, the fine particles on the active areas of the coarse particles are released with the active agents and effectively transmitted to the lungs. If a formulation lacks fine particles, when the coarse particles get caught in the upper respiratory tract, active agent is released there and cannot reach the lungs. In another aspect, fine particles can fly without coarse particles and remain in the patient's mouth. Consequently, it provides advantages in the treatment that cellobiose comprised in the dry powder formulation of the present invention has two different particle sizes.
Average particle size of cellobiose particles comprised in the pharmaceutical composition of the present invention is smaller than 10 μιη, preferably smaller than 5 μηι and more preferably smaller than 3 μηι. Average particle size of the coarse cellobiose particles, on the other hand, is in the range of 10 to 1000 μπι, preferably in the range of 100 to 600 μιη and more preferably in the range of 150 to 300 μπι.
According to the present invention, long-acting p2-agonist and/or pharmaceutically acceptable derivatives thereof in the medicament formulation comprises pharmaceutically acceptable solvates, hydrates, enantiomers or diastereomers, racemates, free base, organic salts, inorganic salts, esters, polymorphs, crystalline forms and amorphous forms of long-acting p2-agonist or a combination thereof.
According to the present invention, long-acting 2-agonist and/or pharmaceutically acceptable derivatives thereof comprised in the dry powder formulation can be selected from a group comprising salmeterol, bambuterol, clenbuterol, formoterol, arformoterol, carmoterol, indacaterol, milveterol, olodaterol or a combination thereof, though it is probably formoterol, arformoterol and carmoterol.
According to the present invention, amount of the active agent in the dry powder formulation comprising long-acting p2-agonist and/or pharmaceutically acceptable derivatives thereof is in the range of 0,01 to 25 μηι, preferably in the range of 0,1 to 20 μιτι and more preferably 0,5 to 15 μπι.
According to another aspect, the present invention provides a medicament comprising long- acting 2-agonist and/or pharmaceutically acceptable derivatives thereof in micronized sizes. Average particle size of long-acting 2-agonist and/or pharmaceutically acceptable derivatives thereof comprised in the formulation of the present invention is in the range of 0,01 to 30 μπι, preferably in the range of 0,05 to 10 μπι and more preferably in the range of 1 to 5 μπι. Adjustment of particle sizes is very important for medicaments administered by the inhalation route. Coarse particles can be caught in the upper respiratory tract after inhaled and this makes it harder for the particles to reach the lungs.
The present invention provides inhalation of the medicament comprising long-acting β2- agonist and/or pharmaceutically acceptable derivatives thereof as active agent and cellobiose as carrier via dry powder inhalers.
In another aspect, the present invention provides inhalation of the dry powder formulation comprising long-acting p2-agonist and/or pharmaceutically acceptable derivatives thereof and cellobiose from a capsule or blister.
In another aspect, the present invention provides administration of the dry powder formulation comprising long-acting 2-agonist and/or pharmaceutically acceptable derivatives thereof and cellobiose in aerosol form. The term "aerosol" refers to dispersion or suspension of a liquid, solution or solid particles in air or gas. According to this, the dry powder formulation can be administered in aerosol form which is characterized by containing propellant gas or not.
According to the present invention, the dry powder formulation comprising cellobiose can additionally comprise other excipients. These excipients can be selected from a group comprising monosaccharides (glucose, etc.), disaccharides (lactose, cellobiose, saccharose, maltose, etc.), oligosaccharides and polysaccharides (dextran, etc.), polyalcohols (sorbitol, mannitol, xyolitol, etc.), salts (sodium chloride, calcium carbonate, etc.), inositol and/or isomers (myoinositol, etc.) or a combination thereof.
According to the present invention, the pharmaceutical composition comprising long-acting β2- agonist and/or pharmaceutically acceptable derivatives thereof can additionally comprise one or more active agents and/or pharmaceutically acceptable derivatives thereof selected from a group comprising anticholinergic, adrenergic agonist, glucocorticosteroid, xanthine, anti leukotriene, PDEIV inhibitor, EGFR inhibitor, anti-allergic, anti-inflammatory, antihistaminic and antimuscarinic substances.
According to the present invention, the pharmaceutical composition comprising long-acting β2- agonist and/or pharmaceutically acceptable derivatives thereof can additionally comprise one or more substances and/or pharmaceutically acceptable derivatives thereof selected from a group comprising anticholinergics such as tiotropium, ipratropium, glycopyrronium and oxytropium; p2-agonists such as salbutamol, fenoterol, terbutaline, carbuterol and pirbuterol; corticosteroids such as beclomethasone, budesonide, ciclesonide, fluticasone and mometasone; xanthines such as doxyphyllin, theobromine, theophylline and aminophylline; antileukotrienes such as montelukast, pranlucast, zafirlukast, ritolukast, sulukast, tomelukast, verlukast, iralukast, ablukast and cinalukast; PDEIV inhibitors such as roflumilast, piclamilast and cilomilast; antihistamines such as levocetirizine, desloratadin, fexofenadine, vapitadine and alcaftadine.
The pharmaceutical composition comprising long-acting p2-agonist and/or pharmaceutically acceptable derivatives thereof according to the present invention can be used in the treatment of many respiratory diseases, particularly in asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD). Accordingly, these respiratory diseases can be, but not limited to, asthma at any stage, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), exacerbation of airway hyperactivity, bronchiectasis, chronic obstructive pulmonary including emphysema and chronic bronchitis, respiratory diseases or lung diseases (COPD, COAD or COLD), pneumoconiosis, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis, byssinosis. This treatment can be prophylactic or symptomatic. In addition, the composition of the present invention is especially used for symptomatic treatment of asthma and COPD.

Claims

Claims:
1. A pharmaceutical composition comprising long-acting p2-agonist and/or pharmaceutically acceptable derivatives thereof as active agent and cellobiose as carrier.
2. The pharmaceutical composition according to claim 1 characterized in that the amount of cellobiose comprised in said composition is in the range of 0-50 mg.
3. The pharmaceutical composition according to claim 2 characterized in that the amount of cellobiose comprised in said composition is in the range of 3-20 mg.
4. The pharmaceutical composition according to claim 1 characterized in that the average particle size of cellobiose comprised in said composition is in the range 0,01 to 1000 μηι.
5. The pharmaceutical composition according to claim 1 characterized in that cellobiose comprised in said composition has two different average particle sizes.
6. The pharmaceutical composition according to claim 5 characterized in that the average particle size of fine cellobiose particles is smaller 10 μηι.
7. The pharmaceutical composition according to claim 6 characterized in that the average particle size of fine cellobiose particles is smaller 5 μπι.
8. The pharmaceutical composition according to claim 7 characterized in that the average particle size of fine cellobiose particles is smaller 3 μπι.
9. The pharmaceutical composition according to claim 5 characterized in that the average particle size of coarse cellobiose particles is in the range of 10 to 1000 μπι.
10. The pharmaceutical composition according to claim 9 characterized in that the average particle size of coarse cellobiose particles is in the range of 100 to 600 μπι.
11. The pharmaceutical composition according to claim 10 characterized in that the average particle size of coarse cellobiose particles is in the range of 150 to 300 μιη.
12. The pharmaceutical composition according to claim 1 characterized in that long-acting p2-agonist and/or pharmaceutically acceptable derivatives thereof is selected from a group comprising salmeterol, bambuterol, clenbuterol, formoterol, arformoterol, carmoterol, indacaterol, milveterol, olodaterol or a combination thereof.
13. The pharmaceutical composition according to claim 12 characterized in that long-acting 2-agonist and/or pharmaceutically acceptable derivatives thereof is selected from a group comprising formoterol, carmoterol or a combination thereof.
14. The pharmaceutical composition according to claim 1 characterized in that said compositions additionally comprises one or more agents and/or pharmaceutically acceptable derivatives thereof selected from a group comprising anticholinergic, adrenergic agonist, glucocorticosteroid, xanthine, anti leukotriene, PDEIV inhibitor, EGFR inhibitor, anti-allergic, anti-inflammatory, antihistaminic and antimuscarinic substances.
PCT/TR2011/000198 2010-09-01 2011-08-24 Formulation comprising cellobiose Ceased WO2012030308A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11776267.4A EP2611431A2 (en) 2010-09-01 2011-08-24 Formulation comprising cellobiose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/07250 2010-09-01
TR2010/07250A TR201007250A2 (en) 2010-09-01 2010-09-01 Formulation containing cellobiose.

Publications (2)

Publication Number Publication Date
WO2012030308A2 true WO2012030308A2 (en) 2012-03-08
WO2012030308A3 WO2012030308A3 (en) 2012-08-09

Family

ID=44883366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000198 Ceased WO2012030308A2 (en) 2010-09-01 2011-08-24 Formulation comprising cellobiose

Country Status (3)

Country Link
EP (1) EP2611431A2 (en)
TR (1) TR201007250A2 (en)
WO (1) WO2012030308A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150202148A1 (en) * 2012-07-05 2015-07-23 Arven llac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose
DE202016008304U1 (en) 2015-01-22 2017-07-05 Pfeifer & Langen GmbH & Co. KG Cellobiose in compositions for consumption or ingestion
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
IT201900008340A1 (en) * 2019-06-07 2020-12-07 Genetic S P A MONTELUKAST SALTS AND THEIR PHARMACEUTICAL COMPOSITIONS
RU2840778C2 (en) * 2019-06-07 2025-05-28 Дженетик С.П.А. Montelukast salts and pharmaceutical compositions containing thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005213A1 (en) 1986-03-04 1987-09-11 Chiesi Farmaceutici S.P.A. New pharmaceutical compositions for inhalation
EP0464171A1 (en) 1990-01-24 1992-01-08 Nat Res Dev Aerosol carriers.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
US6482429B1 (en) * 2001-06-20 2002-11-19 Boehringer Ingelheim Pharmaceuticals, Inc. Stable powder inhalation dosage formulation
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB0312148D0 (en) * 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
JP2009513531A (en) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド Inhalable pharmaceutical formulations containing sugar esters

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005213A1 (en) 1986-03-04 1987-09-11 Chiesi Farmaceutici S.P.A. New pharmaceutical compositions for inhalation
EP0464171A1 (en) 1990-01-24 1992-01-08 Nat Res Dev Aerosol carriers.

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150202148A1 (en) * 2012-07-05 2015-07-23 Arven llac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose
EP2682097B1 (en) 2012-07-05 2016-10-05 Arven Ilac Sanayi Ve Ticaret A.S. Dry Powder Inhalers Comprising A Carrier Other Than Lactose
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
DE202016008304U1 (en) 2015-01-22 2017-07-05 Pfeifer & Langen GmbH & Co. KG Cellobiose in compositions for consumption or ingestion
IT201900008340A1 (en) * 2019-06-07 2020-12-07 Genetic S P A MONTELUKAST SALTS AND THEIR PHARMACEUTICAL COMPOSITIONS
WO2020245358A1 (en) * 2019-06-07 2020-12-10 Genetic S.P.A. Montelukast salts and pharmaceutical compositions containing the same
US20220218690A1 (en) * 2019-06-07 2022-07-14 Genetic S.P.A. Montelukast salts and pharmaceutical compositions containing the same
RU2840778C2 (en) * 2019-06-07 2025-05-28 Дженетик С.П.А. Montelukast salts and pharmaceutical compositions containing thereof
US12453727B2 (en) 2019-06-07 2025-10-28 Genetic S.P.A. Montelukast salts and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
WO2012030308A3 (en) 2012-08-09
TR201007250A2 (en) 2012-03-21
EP2611431A2 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
WO2011136754A1 (en) A medicament developed for the treatment of respiratory diseases
EP2575786B1 (en) Process for dry powder formulations
TWI565481B (en) Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
IL143986A (en) Combinations of formoterol and a tiotropium salt
RS56848B1 (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
CA2948553A1 (en) Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd
WO2011136753A1 (en) Combination of carmoterol and fluticasone for use in the treatment respiratory diseases
EP2682098A2 (en) Inhalation Compositions
WO2012030308A2 (en) Formulation comprising cellobiose
US20100210611A1 (en) Combination therapy
WO2013009271A1 (en) New improved dry powder formulation
WO2012166070A1 (en) Dry powder formulation with improved flow characteristics
WO2012030309A2 (en) Formulation of calcium channel blocker
WO2011136752A1 (en) Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
JP7712916B2 (en) Novel carrier particles for dry powder formulations for inhalation
HK40064779A (en) Novel carrier particles for dry powder formulations for inhalation
TR2023014905A1 (en) AEROSOL COMPOSITIONS CONTAINING STEROIDS
TR2023012447A1 (en) LIQUID PHARMACEUTICAL COMPOSITIONS WITHOUT PROPELLANT GAS
TR2023014979A1 (en) AEROSOL COMPOSITIONS CONTAINING A BETAMIMETIC ACTIVE SUBSTANCE IN INHALEABLE FORM
TR2023016012A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A BETA-MIMETIC ACTIVE SUBSTANCE FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES
TR2023016009A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A MUSCARINIC ANTAGONIST ACTIVE SUBSTANCE SUITABLE FOR INHALATIONAL USE
TR2023014983A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A BETAMIMETIC ACTIVE SUBSTANCE IN INHALEABLE FORM
TR201818680T4 (en) A process for the preparation of formulations for inhalation.
TR2023016002A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A STEROID ACTIVE SUBSTANCE SUITABLE FOR INHALATION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11776267

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011776267

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: DE